Search

The diagnosis of rare diseases and other genetic conditions can be daunting due to vague or poorly defined clinical features that are not recognized even by experienced clinicians. Next-generation sequencing technologies, such as whole-genome sequencing (WGS) and whole-exome sequencing (WES), have greatly enhanced the diagnosis of genetic diseases by expanding the ability to sequence a large part of the genome, rendering a cost-effectiveness comparison between them necessary. Objective To assess the cost-effectiveness of WGS compared with WES and conventional testing in children with suspected genetic disorders. Design, Setting, and Participants In this economic evaluation, a bayesian Markov model was implemented from January 1 to June 30, 2023. The model was developed using data from a cohort of 870 pediatric patients with suspected genetic disorders who were enrolled and underwent testing in the Ospedale Pediatrico Bambino Gesu, Rome, Italy, from January 1, 2015, to December 31, 2022. The robustness of the model was assessed through probabilistic sensitivity analysis and value of information analysis. Main Outcomes and Measures Overall costs, number of definitive diagnoses, and incremental cost-effectiveness ratios per diagnosis were measured. The cost-effectiveness analyses involved 4 comparisons: first-tier WGS with standard of care; first-tier WGS with first-tier WES; first-tier WGS with second-tier WES; and first-tier WGS with second-tier WGS. Results The ages of the 870 participants ranged from 0 to 18 years (539 [62%] girls). The results of the analysis suggested that adopting WGS as a first-tier strategy would be cost-effective compared with all other explored options. For all threshold levels above euro29 800 (US $32 408) per diagnosis that were tested up to euro50 000 (US $54 375) per diagnosis, first-line WGS vs second-line WES strategy (ie, 54.6%) had the highest probability of being cost-effective, followed by first-line vs second-line WGS (ie, 54.3%)

Background: Although the long-term consequences of the Coronavirus Disease-2019 (COVID-19) pandemic are yet to be fully comprehended, a syndrome symptomatically akin to the COVID-19 disease has been defined, for children and adolescents, in February 2023 by the World Health Organization (WHO) as ‘post COVID-19 condition’ (PCC). Potential consequences of COVID-19 that affect developmental milestones in children and adolescents should be comprehended in their magnitude and duration. The aim is to investigate the most common symptoms and predictors or risk factors for pediatric PCC. Methods: In this umbrella review, the population of interest was defined as children and adolescents from 0 to 19 years old presenting PCC symptoms as defined by the WHO in the International Classification of Diseases. The intervention considered was general follow-up activity to monitor the patients’ recovery status. No comparator was chosen, and the outcomes were symptoms of PCC and predictors or risk factors of developing PCC. Methodological quality, risk of bias and the level of overlap between studies were assessed. A random- effects meta-analytic synthesis of respective estimates with inverse variance study weighting was carried out, for the primary studies included by the reviews retrieved, regarding predictors or risk factors reported. Results: We identified six eligible systematic reviews, five with meta-analyses, from three databases. The most common symptoms reported were fatigue and respiratory difficulties; female sex and older age were the most reported factors associated with the development of pediatric PCC. Conclusions: A deeper understanding of pediatric PCC requires well- designed and clearly defined prospective studies, symptom differentiation, and adequate follow-up.

AimsCardiac contractility modulation (CCM) is a device therapy for heart failure, based on the delivery of high-voltage biphasic impulses to the right ventricular septum during the myocardial absolute refractory period. This study evaluated the cost-effectiveness of CCM therapy plus optimal medical therapy (OMT) vs. OMT alone in patients with heart failure with reduced ejection fraction.Methods and resultsA Markov model with a lifespan time horizon was developed to assess the cost-utility using the FIX trials as main data sources. A deterministic sensitivity analysis and a probabilistic sensitivity analysis were run to analyse the decision uncertainty in the model through cost-effectiveness acceptability curve (CEAC) and cost-effectiveness acceptability frontier (CEAF). Value of information analysis was also conducted computing the expected value of perfect information (EVPI) and the expected value of partial perfect information. The base case results showed that the CCM plus OMT option was highly cost-effective compared with OMT alone with an incremental cost-utility ratio of euro7034/quality-adjusted life year (QALY). The CEAC and CEAF illustrated that for all willingness to pay levels above euro5600/QALY, tested up to euro50 000/QALY, CCM plus OMT alternative had the highest probability of being cost-effective. The EVPI per patient was estimated to be euro124 412 on a willingness to pay threshold of euro30 000/QALY.ConclusionsFor patients with heart failure with reduced ejection fraction, CCM therapy could be cost-effective when taking a lifetime horizon. Further long-term, post-approval clinical studies are needed to verify these results in a real-world context, particularly concerning the effect of CCM therapy on mortality.

The concurrent administration of COVID-19 and influenza vaccines has arisen as a promising approach to bolster protection against respiratory pathogens and improve vaccination rates. However, there remains a lack of data regarding the prevalence of co-administration across several vaccination campaigns, especially among healthcare workers (HCWs). Therefore, this study aims to shed light on the acceptance of co-administration strategies among HCWs during the two campaigns following the introduction of the anti-SARS-CoV-2 vaccine. A retrospective cohort study was conducted among the HCWs of the Fondazione Policlinico Universitario "A. Gemelli" IRCCS, a research hospital in Rome. Hospital administrative databases were accessed to gather information about vaccination for SARS-CoV-2 and influenza during the 2021/2022 and 2022/2023 vaccination campaigns. The study included 7399 HCWs. The co-administration of anti-SARS-CoV-2 and influenza vaccines presented a significant rise in 2022/2023 compared to the previous vaccination campaign (+38%): this was confirmed for every professional category, with the largest increases among resident doctors (+47%) and physicians (+44%), and also for every age category, but it was particularly evident for the youngest health professionals. The probability of co-administration uptake during the 2022/2023 campaign was significantly higher for males, and for those that received co-administration during the 2021/2022 campaign, while the probability was lower for nurses and administrative staff. This study highlights the co-administration procedure as a valuable and effective tool in annual vaccination campaigns for SARS-CoV-2 and influenza. The procedure's safety and streamlined logistics make it increasingly attractive for implementation, particularly among HCWs.

This study explores the organizational aspects of whole genome sequencing (WGS) implementation for pediatric patients with suspected genetic disorders in Italy, comparing it with whole exome sequencing (WES). Health professionals' opinions were collected through an internet-based survey and analyzed using a qualitative summative content analysis methodology. Among the 16 respondents, most were clinical geneticists performing only WES, while 5 also used WGS. The key differences identified include higher needs for analyzing genome rearrangements following WES, greater data storage and security requirements for WGS, and WGS only being performed in specific research studies. No difference was detected in centralization and decentralization issues. The main cost factors included genetic consultations, library preparation and sequencing, bioinformatic analysis, interpretation and confirmation, data storage, and complementary diagnostic investigations. Both WES and WGS decreased the need for additional diagnostic analyses when not used as last-resort tests. Organizational aspects were similar for WGS and WES, but economic evidence gaps may exist for WGS in clinical settings. As sequencing costs decline, WGS will likely replace WES and traditional genetic testing. Tailored genomic policies and cost-effectiveness analyses are needed for WGS implementation in health systems. WGS shows promise for enhancing genetics knowledge and expediting diagnoses for pediatric patients with genetic disorders.

SARS-CoV-2 vaccination has been the most effective tool to prevent COVID-19, significantly reducing deaths and hospitalizations worldwide. Vaccination has played a huge role in bringing the COVID-19 pandemic under control, even as the inequitable distribution of vaccines still leaves several countries vulnerable. Therefore, organizing a mass vaccination campaign on a global scale is a priority to contain the virus spread. The aim of this systematic review was to assess whether COVID-19 vaccination campaigns are cost-effective with respect to no vaccination. A systematic literature search was conducted in the WHO COVID-19 Global literature database, PubMed, Web of Science, Embase, and Scopus from 2020 to 2022. Studies assessing the COVID-19 vaccination campaign cost-effectiveness over no vaccination were deemed eligible. The "Drummond's checklist" was adopted for quality assessment. A synthesis of the studies was performed through the "dominance ranking matrix tool". Overall, 10 studies were considered. COVID-19 vaccination was deemed cost-effective in each of them, and vaccination campaigns were found to be sustainable public health approaches to fight the health emergency. Providing economic evaluation data for mass vaccination is needed to support decision makers to make value-based and evidence-based decisions to ensure equitable access to vaccination and reduce the COVID-19 burden worldwide.

Background: The World Health Organization identified alcohol and tobacco consumption as the risk factors with a greater attributable burden and number of deaths related to non-communicable diseases. A promising technique aimed to modify behavioral risk factors by redesigning the elements influencing the choice of people is nudging. Methodology: A scoping review of the literature was performed to map the literature evidence investigating the use of nudging for tobacco and alcohol consumption prevention and/or control in adults. Results: A total of 20 studies were included. The identified nudging categories were increasing salience of information or incentives (IS), default choices (DF), and providing feedback (PF). Almost three-quarters of the studies implementing IS and half of those implementing PF reported a success. Three-quarters of the studies using IS in conjunction with other interventions reported a success whereas more than half of the those with IS alone reported a success. The PF strategy performed better in multi-component interventions targeting alcohol consumption. Only one DF mono-component study addressing alcohol consumption reported a success. Conclusions: To achieve a higher impact, nudging should be integrated into comprehensive prevention policy frameworks, with dedicated education sessions for health professionals. In conclusion, nudge strategies for tobacco and alcohol consumption prevention in adults show promising results. Further research is needed to investigate the use of nudge strategies in socio-economically diverse groups and in young populations.

Background and aims: Transvenous lead extraction (TLE) has become a pivotal part of a comprehensive lead management strategy, dealing with a continuously increasing demand. Nonetheless, the literature about the long-term impact of TLE on survivals is still lacking. Given these knowledge gaps, the aim of our study was to analyse very long-term mortality in patients undergoing TLE in public health perspective. Methods: This prospective, single-centre, observational study enrolled consecutive patients with cardiac implantable electronic device (CIED) who underwent TLE, from January 2005 to January 2021. The main goal was to establish the independent predictors of very long-term mortality after TLE. We also aimed at assessing procedural and hospitalization-related costs. Results: We enrolled 435 patients (mean age 70 ± 12 years, with mean lead dwelling time 6.8 ± 16.7 years), with prevalent infective indication to TLE (92%). Initial success of TLE was achieved in 98% of population. After a median follow-up of 4.5 years (range: 1 month-15.5 years), 150 of the 435 enrolled patients (34%) died. At multivariate analysis, death was predicted by: age (≥77 years, OR: 2.55, CI: 1.8-3.6, p < 0.001), chronic kidney disease (CKD) defined as severe reduction of estimated glomerular filtration rate (eGFR <30 mL/min/1.73 m2 , OR: 1.75, CI: 1.24-2.4, p = 0.001) and systolic dysfunction assessed before TLE defined as left ventricular ejection fraction (LVEF) <40%, OR: 1.78, CI 1.26-2.5, p = 0.001. Mean extraction cost was €5011 per patient without reimplantation and €6336 per patient with reimplantation respectively. Conclusions: Our study identified three predictors of long-term mortality in a high-risk cohort of patients with a cardiac device infection, undergoing successful TLE. The future development of a mortality risk score before might impact on public health strategy.

Obiettivi - Stimare la costo-efficacia dei pacemaker leadless (PL) rispetto ai pacemaker tradizionali (PT) nella popolazione eleggibile per l’impianto di PL e PT dalla prospettiva del Servizio Sanitario Nazionale (SSN). Metodologia - Un albero decisionale Bayesiano è stato calibrato per una coorte ipotetica di pazienti divisi equamente nel braccio PL e nel braccio PT, adottando la prospettiva del SSN. Dopo che il paziente è stato impiantato, può incorrere con probabilità prede- terminate in una complicanza. La popolazione target consisteva di pazienti eleggibili per l’impianto di PL e PT e ai quali viene impiantato uno dei due tipi di device. I parametri del modello sono stati ottenuti dalla letteratura scientifica. In particolare, i costi dei device, il costo medio delle complicanze ad essi associate e le probabilità di transizione sono stati derivati rispettivamente da un report statale statunitense [1], uno studio economico nazionale francese [2] e una revisione sistematica con meta-analisi [3]. I costi e i bene- fici sono stati scontati a un tasso annuo del 3%. Per orientare il processo decisionale su quale alternativa supportare è stato scelto il threshold dell’Eurozona, che varia da € 30.000 a € 50.000. L’impatto dell’incertezza sui parametri del modello è stato esplorato attraverso un’analisi di sensibilità probabilistica (PSA), calcolando la curva di accettabilità della costo-efficacia (CEAC) e la frontiera di accettabilità della costo-efficacia (CEAF), e un’analisi del valore dell’informazione (VOI), stimando invece il valore atteso dell’informa- zione perfetta (EVPI). L’inferenza Bayesiana è stata supportata da una serie di algoritmi noti come Markov Chain Monte Carlo (MCMC), tra cui il Gibbs sampler. È stata inoltre valutata la performance dell’algoritmo selezionato attraverso l’impiego di alcune tecni- che diagnostiche (i.e., traceplot, grafici di densità, diagnostica di Gelman-Rubin, funzioni di autocorrelazione della catena). I risultati d

Obiettivi - Lo Scompenso Cardiaco (SC) comporta un onere importante per il nostro Ser- vizio Sanitario Nazionale ed è associato ad un elevato carico di malattia legato ai costi, diretti e indiretti, che vengono generati dalla gestione della patologia stessa. La Cardiac Contractility Modulation (CCM) potrebbe rappresentare una nuova possibilità terapeutica per i pazienti con SC. Il presente progetto si propone, pertanto, mediante il coinvolgimen- to di diversi professionisti della salute (cardiologi, elettrofisiologi, professionisti di sanità pubblica) di analizzare e sistematizzare le evidenze attualmente disponibili sulla CCM, al fine di identificare gli elementi chiave per una possibile implementazione di questa tecno- logia innovativa nel contesto di cura italiano. Metodologia - È stata condotta un’analisi della letteratura scientifica sul burden epide- miologico dello SC, sulle caratteristiche del percorso di cura e sull’assorbimento delle risorse per il trattamento dello SC, nonché sulle evidenze scientifiche attualmente dispo- nibili sulla CCM. Risultati - Il burden dello SC riguarda 64,3 milioni di persone in tutto il mondo, diven- tando sempre più comune nei pazienti di età pari o superiore a 65 anni. Circa il 50% dei pazienti con SC muore entro 5 anni dalla diagnosi e si stima che questa sindrome inte- resserà più di 8 milioni di persone nel 2030. Nel corso degli ultimi anni, nuovi trattamenti, farmacologici e no, sono stati sviluppati per la gestione dello SC, come, ad esempio, terapie farmacologie (valsartan, ivabradina ecc.), la terapia di resincronizzazione cardiaca (CRT) e l’ablazione della fibrillazione atriale. Tuttavia, queste opportunità terapeutiche si sono dimostrate efficaci solo nello SC a Frazione di Eiezione (FE) ridotta. Risulta, quindi, essenziale identificare strategie farmacologiche ed elettriche alternative, soprattutto in considerazione del fatto che circa il 50% dei pazienti è affetto da SC a FE ridotta e che solo il 30% dei

This study investigates the financial consequences of perceived discrimination towards LGBTQAI+ people in Italy, focusing on psychological support and medication costs. It highlights the burden of discriminatory experiences, emphasizing the need for policies to minimize costs. A cost analysis was performed according to the NHS perspective. A purposive sample was recruited through a web-based survey spread on Italian researchers’ social networks, asking any LGBTQAI+ readers to answer about discriminatory experiences, access to psychological support, and medication use. Costs of health services use were estimated according to the Italian NHS tariffs and Italian Psychologists’ Board. The time horizon was set at one year and discounting was not necessary. Robustness was checked by a one-way sensitivity analysis. A total of 75 LGBTQAI+ people completed the survey. Most of them (aged 26-35 years, 85%; residing in big cities, 70%; unaffiliated with LGBTQAI+ associations, 88%) reported discriminative actions (60%), with 15% seeking psychological help soon after being victim of a single discriminatory act. Verbal and physical abuse were reported by 88% and 6% respectively. 40% of respondents claimed to have resorted to psychotherapy sessions because of the discomfort felt after acts perceived as discriminatory or violent, amounting to 810 total therapy hours. The total therapy cost was E72,900, of which 60% paid as out-of-pocket expenses, and 40% partially covered by regional Local Health Units. Additionally, 12% of respondents used SSRI or benzodiazepines, costing the National Health System an esteemed E3054. The sensitive analysis confirmed the robustness of results. The study demonstrates the significant economic burden of discrimination against LGBTQAI+ individuals in Italy, emphasizing the need for inclusive policies and accessible mental health support. Further research is required to explore indirect costs, for a comprehensive understanding of the total economic impac

Community-based participatory research (CBPR) is one of the most used community engagement frameworks to promote health changes in vulnerable populations. The more a community is engaged, the more a program can impact the social determinants of health. The present study aims to measure the level of engagement reached in randomized controlled trials (RCTs) using CBPR in disadvantaged populations, and to find out the CBPR components that better correlate with a higher level of engagement. A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Embase, Web of Science, MEDLINE, Cochrane and Scopus databases were queried. Engagement level was assessed using the revised version of IAP2 spectrum, ranging from "inform" to "shared leadership" . Fifty-one RCTs were included, belonging to 36 engagement programs. Fourteen CBPR reached the highest level of engagement. According to the multivariate logistic regression, a pre-existing community intervention was associated with a higher engagement level (OR = 10.08; p<0.05).The variable "institutional funding" was perfectly correlated with a higher level of engagement. No correlation was found with income status or type of preventive programs. A history of collaboration seems to influence the effectiveness in involving communities burdened with social inequities, so starting new partnerships remains a public health priority to invest on. A strong potentiality of CBPR was described in engaging disadvantaged communities, addressing social determinants of health.The key findings described above should be taken into account when planning a community engagement intervention, to build up an effective collaborative field between researchers and population.

The efficacy of the first schedule of COVID-19 mRNA vaccines has decreased after the surge of the Delta variant, posing the need to administer a booster dose to enhance the neutralising immune response. This study aims at evaluating the duration of protection given by the booster dose of Pfizer-BioNTech BNT162b2 mRNA vaccine in healthcare workers (HCWs) of a large teaching hospital in Rome and to analyse the factors associated with post-booster vaccination infections. Data about vaccinations of HCWs with the BNT162b2 vaccine and nasal swabs positive for SARS-CoV-2 were extracted from the digital archives of the hospital from 27 September 2021 to 31 May 2022. In total, 5770 HCWs were observed. The cumulative risk of becoming infected by SARS-CoV-2 increased with time (2.5% at 4 weeks, 17% at 12 weeks and 40% at 24 weeks) and was significantly higher for females, younger classes of patients and for those who had developed a hybrid immunity (natural infection plus one dose, namely the primary schedule, added to the booster dose) compared to those who had completed the three doses. This study describes the duration and the determinants of the protection against infections after the booster dose of COVID-19 vaccine, highlighting the need for continuous monitoring of vaccine-induced immunogenicity.

Vaccinations generate health, economic and social benefits in both vaccinated and unvaccinated populations. The aim of this study was to conduct a cost–benefit analysis to estimate the costs and benefits associated with the COVID-19 vaccination campaign for health workers in Fondazione Policlinico Universitario Agostino Gemelli IRCCS (FPG). The analysis included 5152 healthcare workers who voluntarily received the Pfizer–BioNTech COVID-19 vaccine, divided into physicians, nurses and other health workers. Data about vaccine cost, administration and materials were derived from administrative databases of the FPG from 28 December 2020 to 31 March 2021. The costs associated with the COVID-19 vaccination campaign amounted to EUR 2,221,768, while the benefits equaled EUR 10,345,847. The benefit-to-cost ratio resulted in EUR 4.66, while the societal return on investment showed a ratio of EUR 3.66. The COVID-19 vaccination campaign for health workers in FPG has high social returns and it strengthens the need to inform and update decision-making about the economic and social benefits associated with a vaccination campaign. Health economic evaluations on vaccines should always be considered by decision-makers when considering the inclusion of a new vaccine into the national program.

As more people live in cities, the impact of urban settings on population health has been increasing. One of the main strategies to cope with urbanization is adopting artificial intelligence (AI) and new digital technologies to develop new urban services that improve citizens’ health and well-being. The aim of this study is to review urban interventions and adopting digital technologies and AI-based algorithms to improve population health. A scoping review of the literature was conducted by querying MEDLINE, Web of Science, and Scopus databases. The included studies were categorized into one urban health area, suggested by the WHO, according to the type of intervention investigated. Out of 3733 records screened, 12 papers met all inclusion criteria. Four studies investigated the “outdoor and indoor pollution” area, one “climate change”, one “housing”, two “health and social services” and four “urban transport” areas. Only one article used a comprehensive approach to public health, investigating the use of AI and digital technologies both to characterize exposure conditions to health determinants and to monitor population health effects, while the others were limited to characterizing exposure conditions to health determinants, thus employing a preliminary public health perspective. From this point of view, countries should foster synergy for the development of research on digital technologies to address the determinants of health in the urban context. From a global health perspective, sharing results with the scientific community would also allow other countries to use those technologies that have been shown to be effective, paving the way for more sustainable living conditions worldwide.

Objective: The aim of this scoping review is to map the available evidence about the use of health technology assessment (HTA) in the assessment of whole genome sequencing (WGS).Methods: A scoping review methodology was adopted. The population, concept, and context framework was used to build up the research question and to establish the eligibility criteria. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews was adopted to implement a comprehensive search strategy. Evidence was retrieved from scientific databases and HTA organizations Web sites. Reports were classified as full HTA, mini-HTA, rapid reviews or other.Results: The search strategy identified seven reports. Five HTA organizations from five countries elaborated the reports: one full HTA, four rapid reviews, and two classified as others. The reports were mainly focused on the evaluation of the clinical utility and cost-effectiveness of genome-wide sequencing as well as informing policy questions by providing analyses of organizational and ethical considerations.Conclusions: Few HTA organizations are drafting reports for WGS. It is essential to stimulate a critical reflection during the elaboration of HTA reports for WGS to steer choices of decision makers in the establishment of priorities for research and policy and reimbursement rates.

Introduction In primary care, almost 75% of outpatient visits by family doctors and general practitioners involve continuation or initiation of drug therapy. Due to the enormous amount of drugs used by outpatients in unmonitored situations, the potential risk of adverse events due to an error in the use or prescription of drugs is much higher than in a hospital setting. Artificial intelligence (AI) application can help healthcare professionals to take charge of patient safety by improving error detection, patient stratification and drug management. The aim is to investigate the impact of AI algorithms on drug management in primary care settings and to compare AI or algorithms with standard clinical practice to define the medication fields where a technological support could lead to better results. Methods and analysis A systematic review and meta-analysis of literature will be conducted querying PubMed, Cochrane and ISI Web of Science from the inception to December 2021. The primary outcome will be the reduction of medication errors obtained by AI application. The search strategy and the study selection will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and the population, intervention, comparator and outcome framework. Quality of included studies will be appraised adopting the quality assessment tool for observational cohort and cross-sectional studies for non-randomised controlled trials as well as the quality assessment of controlled intervention studies of National Institute of Health for randomised controlled trials. Ethics and dissemination Formal ethical approval is not required since no human beings are involved. The results will be disseminated widely through peer-reviewed publications.

The global spread of diabetes poses serious threats to public health requiring a patient-centered approach based both on interprofessional collaboration (IPC) given by the cooperation of several different health professionals, and patients' perspective through the assessment of Patient-Reported Outcomes (PROs). The aim of the present study is to evaluate the impact of interprofessional collaboration interventions, for the management of type 2 diabetes in primary care settings, through PROs. A systematic review and meta-analysis was conducted querying the PubMed, Scopus and Embase databases. Out of the 1961 papers initially retrieved, 19 met the inclusion criteria. Interprofessional collaboration is significantly associated with an increase in both patient's satisfaction (SMD 0.32 95% CI 0.05-0.59) and in the mental well-being component of the HRQoL (SMD 0.18; 95% CI 0.06-0.30), and there was also promising evidence supporting the association between an interprofessional approach and an increase in self-care and in generic and specific quality-of-life. No statistical differences were found, supporting the positive impact on IPC interventions on the physical component of the HRQoL, depression, emotional distress, and self-efficacy. In conclusion, the effect of IPC impacts positively on the few areas assessed by PROMs. Policymakers should promote the widespread adoption of a collaborative approach as well as to endorse an active engagement of patients across the whole process of care.

Obiettivi - Redigere un questionario volto ad indagare il dominio degli aspetti organizzativi (ORG) legati all’implementazione e all’utilizzo della tecnologia diagnostica di Whole Ge- nome Sequencing (WGS). Metodologia - Successivamente all’estrazione dei risultati delle analisi delle corrispon- denze multiple relative alle tecnologie diagnostiche effettuata da Cacciatore et al., sono state identificate le quattro issue EUnetHTA alle quali far riferimento, secondo l’autore, per studiare il dominio ORG (G0004, G0005, G0006, D0023). Seguendo le indicazioni del Core Model 3.0 di EUnetHTA, con particolare attenzione rivolta alle Assessment element card delle sopracitate issue, ed in seguito allo studio della letteratura e dei report HTA che descrivono gli aspetti organizzativi della WGS, è stato redatto un questionario mediante l’applicazione web Google Forms. Per progettare il questionario è stata inoltre seguita la guida di Boparai et al. Il questionario sarà distribuito a mezzo posta elettronica ai centri clinici italiani che fanno uso della WGS. Risultati - Le domande risultanti a risposta aperta e a risposta multipla sono distribuite in 6 sezioni, di cui le ultime 4 derivanti in maniera univoca dalle 4 issue predeterminate, ed indagano le seguenti aree concettuali: le caratteristiche del partecipante al questionario (4 domande) e del centro presso cui lavora (2 domande), le attività e le risorse associate all’impiego della WGS (1 domanda), gli attori con i quali il partecipante si interfaccia e le azioni che intercorrono affinché i processi relativi alla WGS (1 domanda) e alla Whole Exo- me Sequencing (WES) (1 domanda) siano eseguiti, i rapporti di cooperazione e/o comuni- cazione con altri centri che ricorrono alla WGS (2 domande), le opinioni sulle facilitazioni o limitazioni nell’accesso alla tecnologia derivanti dalla centralizzazione (2 domande) della stessa, le opinioni sui vantaggi e svantaggi economici e qualitativi derivanti dalla decen- tralizzazione

Objectives: The aim of this study is to investigate the effect of artificial intelligence (AI) and/or algorithms on drug management in primary care settings comparing AI and/or algorithms with standard clinical practice. Second, we evaluated what is the most frequently reported type of medication error and the most used AI machine type. Methods: A systematic review of literature was conducted querying PubMed, Cochrane and ISI Web of Science until November 2021. The search strategy and the study selection were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and the Population, Intervention, Comparator, Outcome framework. Specifically, the Population chosen was general population of all ages (ie, including paediatric patients) in primary care settings (ie, home setting, ambulatory and nursery homes); the Intervention considered was the analysis AI and/or algorithms (ie, intelligent programs or software) application in primary care for reducing medications errors, the Comparator was the general practice and, lastly, the Outcome was the reduction of preventable medication errors (eg, overprescribing, inappropriate medication, drug interaction, risk of injury, dosing errors or in an increase in adherence to therapy). The methodological quality of included studies was appraised adopting the Quality Assessment of Controlled Intervention Studies of the National Institute of Health for randomised controlled trials. Results: Studies reported in different ways the effective reduction of medication error. Ten out of 14 included studies, corresponding to 71% of articles, reported a reduction of medication errors, supporting the hypothesis that AI is an important tool for patient safety. Conclusion: This study highlights how a proper application of AI in primary care is possible, since it provides an important tool to support the physician with drug management in non-hospital environments.

Introduzione L’ablazione transcatetere è una terapia efficace per il controllo del ritmo nella fibrillazione atriale (FA). L’obiettivo dello studio è confrontare i costi dell’ablazione transcatetere della FA eseguita rispettivamente con TactiFlex e TactiCath in uno scenario ospedaliero reale. Metodi Assunta la medesima efficacia e sicurezza cliniche per le due alternative, è stata effettuata un'analisi di minimizzazione dei costi per valutarne l’impatto economico. Le durate medie delle due proce- dure sono state calcolate su un campione di pazienti trattati presso un ospedale italiano. Le analisi dei costi medici diretti e non medici diretti sono state effettuate adottando la prospettiva dell'ospe- dale. È stata condotta un'analisi di sensibilità univariata per valutare l’incertezza nei parametri scelti. Risultati Dalla prospettiva dell'ospedale, si stima preliminarmente che la procedura con TactiFlex costi €168 in più rispetto all'alternativa, con un guadagno medio di 57.3±9.5 minuti nella disponibilità della sala operatoria impiegata e del personale coinvolto nell’ablazione. I parametri maggiormente deter- minanti l’incertezza nei risultati sono i salari orari del personale e i costi dei cateteri ablatori. Conclusioni L’adozione del catetere TactiFlex può aumentare l'efficienza nell’impiego delle sale operatorie e del personale coinvolto nelle ablazioni della FA, e ridurre il rischio di complicanze attribuibile alla maggior durata dell’anestesia.

Introduzione L’ablazione transcatetere è una terapia efficace per il controllo del ritmo nella fibrillazione atriale (FA). L’obiettivo dello studio è confrontare i costi dell’ablazione transcatetere della FA eseguita rispettivamente con TactiFlex e TactiCath in uno scenario ospedaliero reale. Metodi Assunta la medesima efficacia e sicurezza cliniche per le due alternative, è stata effettuata un'analisi di minimizzazione dei costi per valutarne l’impatto economico. Le durate medie delle due proce- dure sono state calcolate su un campione di pazienti trattati presso un ospedale italiano. Le analisi dei costi medici diretti e non medici diretti sono state effettuate adottando la prospettiva dell'ospe- dale. È stata condotta un'analisi di sensibilità univariata per valutare l’incertezza nei parametri scelti. Risultati Dalla prospettiva dell'ospedale, si stima preliminarmente che la procedura con TactiFlex costi €168 in più rispetto all'alternativa, con un guadagno medio di 57.3±9.5 minuti nella disponibilità della sala operatoria impiegata e del personale coinvolto nell’ablazione. I parametri maggiormente deter- minanti l’incertezza nei risultati sono i salari orari del personale e i costi dei cateteri ablatori. Conclusioni L’adozione del catetere TactiFlex può aumentare l'efficienza nell’impiego delle sale operatorie e del personale coinvolto nelle ablazioni della FA, e ridurre il rischio di complicanze attribuibile alla maggior durata dell’anestesia.

The COVID-19 pandemic called for a reorganisation of the methods for providing health services. The aim of this paper is to describe the organisational model implemented by one of Rome's Local Health Units (LHU), ASL Roma 1, for the "at-home COVID-19 vaccination campaign " dedicated to a target population and to outline data related to vaccination coverage stratified by health districts. A cross-sectional study was designed to describe the strategies implemented by LHU to deliver at-home vaccination programmes. People eligible for the at-home vaccination programme included patients living in the area of the LHU, being assisted by the district home care centre or not transportable or individuals with social situations that make traveling difficult. Priority for vaccination was given to (I) age > 80 years, (II) ventilated patients with no age limit, (III) very seriously disabled people with no age limit. Patients' data were acquired from regional and LHU databases. From 5 February until the 16 May, 6127 people got at least one dose of Pfizer-Biontech Comirnaty(R) vaccine, while 5278 (86.14%) completed the necessary two doses. The highest number of vaccines was administered during the first week of April, reaching 1296 doses overall. The number of vaccines administered were similar across the districts. The average number of people vaccinated at home was 6 per 1000 inhabitants in the LHU. This model proved to be extremely complex but effective, reaching satisfying results in terms of vaccination coverage.